Rachel Thijssen

2.9k total citations · 1 hit paper
29 papers, 932 citations indexed

About

Rachel Thijssen is a scholar working on Genetics, Molecular Biology and Immunology. According to data from OpenAlex, Rachel Thijssen has authored 29 papers receiving a total of 932 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Genetics, 16 papers in Molecular Biology and 8 papers in Immunology. Recurrent topics in Rachel Thijssen's work include Chronic Lymphocytic Leukemia Research (25 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Cell death mechanisms and regulation (5 papers). Rachel Thijssen is often cited by papers focused on Chronic Lymphocytic Leukemia Research (25 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Cell death mechanisms and regulation (5 papers). Rachel Thijssen collaborates with scholars based in Australia, Netherlands and France. Rachel Thijssen's co-authors include David C.S. Huang, Andrew W. Roberts, Mary Ann Anderson, Eric Eldering, Piers Blombery, Richard W. Birkinshaw, Peter E. Czabotar, Jianan Gong, Ian J. Majewski and Arnon P. Kater and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and Blood.

In The Last Decade

Rachel Thijssen

29 papers receiving 921 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

2018 276 citations Piers Blombery, Mary Ann Anderson et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rachel Thijssen Australia	15	457	408	271	239	221	29	932
Jianning Yang United States	14	254 0.6×	320 0.8×	237 0.9×	125 0.5×	220 1.0×	29	693
Saravanan Yuvaraj Netherlands	12	328 0.7×	356 0.9×	216 0.8×	293 1.2×	155 0.7×	16	807
Francesco Paolo Tambaro United States	16	262 0.6×	789 1.9×	211 0.8×	187 0.8×	309 1.4×	40	1.3k
Lugui Qiu China	17	236 0.5×	483 1.2×	183 0.7×	222 0.9×	315 1.4×	125	1.0k
Amanda Copeland United States	15	315 0.7×	536 1.3×	558 2.1×	166 0.7×	623 2.8×	36	1.2k
Seong Lin Khaw Australia	17	440 1.0×	958 2.3×	252 0.9×	245 1.0×	440 2.0×	37	1.6k
Qingshan Li China	11	523 1.1×	394 1.0×	57 0.2×	129 0.5×	260 1.2×	24	874
Violetta V. Leshchenko United States	14	101 0.2×	576 1.4×	152 0.6×	105 0.4×	230 1.0×	54	808
Hua Dong China	10	256 0.6×	290 0.7×	48 0.2×	147 0.6×	213 1.0×	28	691
Timothy P. Heffernan United States	18	176 0.4×	837 2.1×	118 0.4×	83 0.3×	476 2.2×	38	1.3k

Countries citing papers authored by Rachel Thijssen

Since Specialization

Citations

This map shows the geographic impact of Rachel Thijssen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Thijssen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Thijssen more than expected).

Fields of papers citing papers by Rachel Thijssen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Thijssen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Thijssen. The network helps show where Rachel Thijssen may publish in the future.

Co-authorship network of co-authors of Rachel Thijssen

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Thijssen. A scholar is included among the top collaborators of Rachel Thijssen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Thijssen. Rachel Thijssen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Peng, Hongke, Jafar S. Jabbari, Luyi Tian, et al.. (2025). Single-cell Rapid Capture Hybridization sequencing reliably detects isoform usage and coding mutations in targeted genes. Genome Research. 35(4). 942–955. 1 indexed citations

Gao, Mingyuan, Angela Georgiou, Victor S. Lin, et al.. (2024). Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implications. British Journal of Haematology. 205(4). 1389–1394. 1 indexed citations

Salim, Agus, Ramyar Molania, Jianan Wang, et al.. (2022). RUV-III-NB: normalization of single cell RNA-seq data. Nucleic Acids Research. 50(16). e96–e96. 7 indexed citations

Thijssen, Rachel, Simon P. Mackay, Julie Dubois, et al.. (2022). JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL. Molecular Oncology. 17(6). 1112–1128. 15 indexed citations

Thompson, Ella R., Tamia Nguyen, John Markham, et al.. (2021). Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors. Blood Advances. 6(2). 503–508. 17 indexed citations

Thijssen, Rachel, Christopher M. West, Louise Young, et al.. (2021). Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL. Cell Death and Differentiation. 28(5). 1658–1668. 66 indexed citations

Teh, Charis E., Tania Tan, Marie Trussart, et al.. (2021). Deep Profiling of Chronic Lymphocytic Leukaemia (CLL) and Healthy Immune Cells By Mass Cytometry Resolves Impacts of Venetoclax Pressure. Blood. 138(Supplement 1). 3710–3710. 1 indexed citations

Lin, Victor S., et al.. (2020). BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the Clinic. Cancers. 12(11). 3353–3353. 15 indexed citations

Thijssen, Rachel, Silvia Álvarez-Díaz, Mingyuan Gao, et al.. (2020). Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells. Cell Death and Differentiation. 27(8). 2531–2533. 8 indexed citations

10.

Birkinshaw, Richard W., Jianan Gong, Cindy S. Luo, et al.. (2019). Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nature Communications. 10(1). 2385–2385. 172 indexed citations

11.

Dengler, Michael A., Charis E. Teh, Rachel Thijssen, et al.. (2019). Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. Oncogene. 39(9). 2009–2023. 18 indexed citations

12.

Blombery, Piers, Mary Ann Anderson, Jianan Gong, et al.. (2018). Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discovery. 9(3). 342–353. 276 indexed citations breakdown →

13.

Blombery, Piers, Mary Ann Anderson, Jianan Gong, et al.. (2018). Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Blood. 132(Supplement 1). LBA–7. 9 indexed citations

14.

Thijssen, Rachel, et al.. (2017). Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. Leukemia. 31(12). 2601–2607. 20 indexed citations

15.

Thijssen, Rachel, Jennifer R. Brown, Stacey M. Fernandes, et al.. (2016). Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood. 128(4). 574–583. 59 indexed citations

16.

Thijssen, Rachel, Martin F. M. de Rooij, Annemieke Kuil, et al.. (2015). The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. Leukemia. 30(2). 337–345. 20 indexed citations

17.

Kater, Arnon P., et al.. (2015). Targeting BCR-Independent Proliferation of CLL Cells. Blood. 126(23). 2916–2916. 1 indexed citations

18.

Thijssen, Rachel, Théo Hofman, & Jaap Ham. (2014). Ecodriving acceptance: An experimental study on anticipation behavior of truck drivers. Transportation Research Part F Traffic Psychology and Behaviour. 22. 249–260. 34 indexed citations

19.

Thijssen, Rachel, Christian R. Geest, Bogdan I. Florea, et al.. (2013). Possible Mechanisms Of Resistance To The Novel BH3-Mimetic ABT-199 In In Vitro Lymph Node Models Of CLL – The Role Of Abl and Btk. Blood. 122(21). 4188–4188. 6 indexed citations

20.

Maas, Chiel, Rachel Thijssen, Anna Malara, et al.. (2013). CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex. Cell Death and Disease. 4(8). e782–e782. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact